New COPD inhaler HSK39004 tested for Long-Term safety in 300 patients
NCT ID NCT07634367
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the long-term safety and effectiveness of an experimental inhaler called HSK39004 in 300 adults aged 40 to 80 with moderate-to-severe COPD. Participants will use the inhaler twice daily for 52 weeks. The main goal is to monitor side effects and see how well the treatment controls the disease over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jiangxi Provincial People's Hospital
Nanchang, Jiangxi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could remote rehab keep COPD patients out of the hospital?
- Chest vibrations may boost lung sample collection
- Sports-Inspired balance training could help COPD patients avoid falls
- Can remote care tame COPD Flare-Ups?
- Can a biologic clear the clogged airways of COPD?
- Can animated videos boost Self-Care in lung disease better than paper brochures?